Literature DB >> 25403940

Breast cancer. Predicting nonresponders--light at the end of the PET tunnel.

Alessia Errico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25403940     DOI： 10.1038/nrclinonc.2014.203

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Authors:  Bruno Coudert; Jean-Yves Pierga; Marie-Ange Mouret-Reynier; Kaldoun Kerrou; Jean-Marc Ferrero; Thierry Petit; Pierre Kerbrat; Pierre-François Dupré; Thomas Bachelot; Philippe Gabelle; Sylvia Giard; David Coeffic; Philippe Bougnoux; Jean-Briac Prevost; Gilles Paintaud; Gilles Thibault; Juana Hernandez; Mathieu Coudert; Laurent Arnould; Alina Berriolo-Riedinger
Journal:  Lancet Oncol       Date:  2014-10-30       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.